Salute e Benessere
Global Minimal Residual Disease Testing Market Gearing Up for Outstanding Expansion at a CAGR of ~11% by 2032 | DelveInsight
To read more about the latest highlights related to the minimal residual disease testing market, get a snapshot of the key highlights entailed in the
Minimal residual disease testing refers to the detection of small numbers of cancer cells that may remain in a patient's body after treatment and are undetectable through standard diagnostic methods. These residual cells can eventually lead to relapse, so identifying them early is critical for managing and monitoring the disease. MRD testing uses highly sensitive techniques such as PCR, next-generation sequencing (NGS), or flow cytometry to quantify these remaining cancer cells at very low levels. It has become particularly important in hematologic malignancies like leukemia and multiple myeloma, where MRD status is an increasingly important prognostic indicator.
Clinicians use MRD results to help assess treatment efficacy and to make decisions about therapy intensification or discontinuation. A negative MRD result often indicates a deeper and more durable response to treatment and is associated with improved survival outcomes. Conversely, the presence of MRD can prompt early therapeutic interventions to prevent full relapse. As diagnostic technology advances, MRD testing is being incorporated into clinical guidelines and drug development as a surrogate endpoint, making it a powerful tool for personalized treatment strategies in oncology.
North America is expected to account for the largest share of the minimal residual disease testing market, driven by multiple key factors. The region's leadership stems largely from the increasing incidence of blood cancers and solid tumors, which is boosting the need for sophisticated diagnostic tools. Furthermore, rapid progress in molecular diagnostic technologies, along with consistent product launches and regulatory approvals by major companies, continues to accelerate market expansion.
In the U.S., the market is further buoyed by ongoing innovation and strategic initiatives from leading industry players. For example, in February 2025 , Myriad Genetics received a foundational patent from the U.S. Patent and Trademark Office for its tumor-informed, high-definition MRD assay, which enhances ctDNA detection using advanced sequencing technologies to achieve highly accurate MRD measurement. Likewise, in May 2025 , Exact Sciences Corp. released clinical validation data from its Beta-CORRECT study under the GALAXY cohort, confirming that its Oncodetect™ MRD test effectively predicts recurrence in stage II–IV colorectal cancer patients, supporting its use in post-treatment monitoring and therapeutic decision-making.
As a result, the combination of growing cancer incidence, advancements in molecular diagnostics, and continuous technological progress with new MRD testing products is projected to substantially drive the growth of the MRD testing market in North America from 2025 to 2032.
To know more about why North America is leading the market growth in the minimal residual disease testing market, get a snapshot of the
The minimal residual disease testing market is experiencing strong growth, driven largely by the such as leukemia, lymphoma, and multiple myeloma. As cancer treatment becomes more personalized, oncologists are relying heavily on MRD testing to detect trace levels of cancer cells that remain after treatment. This enables , which is pushing hospitals and cancer research centers to adopt advanced MRD technologies.
are a major catalyst in shaping market dynamics. are enabling clinicians to monitor disease burden with far greater precision than ever before. As these tests prove their clinical value in improving patient outcomes, major diagnostic companies are . Moreover, regulatory agencies like the FDA are granting clearances and , building confidence among healthcare providers and accelerating market adoption.
are also contributing to growth. Pharma companies increasingly incorporate MRD status as a key endpoint in clinical trials for novel oncology drugs. This is boosting the demand for companion diagnostics and driving partnerships across the value chain. is also rising, which adds to innovation and competition in the market.
However, market expansion still faces challenges. Despite significant progress, the in some regions can hinder widespread adoption. Healthcare systems in emerging markets may needed for these tests. In addition, there is , making it difficult to compare results across platforms and institutions.
Get a sneak peek at the minimal residual disease testing market dynamics @
Which MedTech key players in the minimal residual disease testing market are set to emerge as the trendsetter explore @
Interested in knowing the minimal residual disease testing market by 2032? Click to get a snapshot of the
report delivers an in-depth understanding of market trends, market drivers, market barriers, and key MRD companies, including among others.
report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key PCR companies, including , among others.
report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key next generation sequencing companies, including , among others.
report delivers an in-depth understanding of market trends, market drivers, market barriers, and key flow cytometry companies, including among others.
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Shruti Thakur
info@delveinsight.com
+14699457679
https://www.delveinsight.com/medical-devices
Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/global-minimal-residual-disease-testing-market-gearing-up-for-outstanding-expansion-at-a-cagr-of-11-by-2032--delveinsight-302534343.html